Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
Over the last 12 months, insiders at Zentalis Pharmaceuticals, Inc. have bought $219,391 and sold $1.05M worth of Zentalis Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Zentalis Pharmaceuticals, Inc. have bought $33.9M and sold $27.55M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Johnson David Michael (director) — $335,886. Blackwell Kimberly (Chief Executive Officer) — $51,448.
The last purchase of 5,000 shares for transaction amount of $51,448 was made by Blackwell Kimberly (Chief Executive Officer) on 2023‑11‑13.
2024-05-31 | Sale | Gallagher Cam | President, Interim CFO | 9,597 0.0136% | $11.98 | $114,972 | -18.73% | |
2024-05-09 | Sale | HAUSMAN DIANA | Chief Medical Officer | 3,356 0.0048% | $12.62 | $42,353 | -9.16% | |
2024-02-12 | Sale | Gallagher Cam | President | 1,173 0.0016% | $11.44 | $13,419 | +9.26% | |
2024-02-12 | Sale | Epperly Melissa B, | Chief Financial Officer | 2,573 0.0036% | $11.44 | $29,435 | +9.26% | |
2024-02-02 | Sale | Gallagher Cam | President | 11,552 0.0155% | $11.54 | $133,310 | +7.77% | |
2024-02-02 | Sale | Epperly Melissa B, | Chief Financial Officer | 8,669 0.0116% | $11.54 | $100,040 | +7.77% | |
2024-02-02 | Sale | Lackner Mark | Chief Scientific Officer | 1,585 0.0021% | $11.54 | $18,291 | +7.77% | |
2024-02-02 | Sale | Paul Andrea | Chief Legal Officer | 3,310 0.0044% | $11.54 | $38,197 | +7.77% | |
2023-11-13 | Blackwell Kimberly | Chief Executive Officer | 5,000 0.0071% | $10.29 | $51,448 | +23.49% | ||
2023-11-10 | Johnson David Michael | director | 17,000 0.0243% | $9.88 | $167,943 | +28.85% | ||
2023-10-04 | Sale | Bunker Kevin D. | Chief Scientific Officer | 6,068 0.0084% | $19.50 | $118,355 | -34.71% | |
2023-10-04 | Sale | Epperly Melissa B, | Chief Financial Officer | 5,482 0.0076% | $19.50 | $106,926 | -34.71% | |
2023-10-04 | Sale | Brownstein Carrie | Chief Medical Officer | 10,628 0.0148% | $19.50 | $207,298 | -34.71% | |
2023-09-11 | Sale | Skvarka Jan | director | 5,000 0.0071% | $25.05 | $125,238 | -46.29% | |
2023-06-20 | Matrix Capital Management Company, LP | 10 percent owner | 4.76M 6.3802% | $22.66 | $107.86M | -48.63% | ||
2023-05-31 | Sale | Gallagher Cam | President | 27,768 0.0473% | $26.27 | $729,506 | -41.32% | |
2023-05-26 | Sale | Bunker Kevin D. | Chief Scientific Officer | 80,000 0.1348% | $30.02 | $2.4M | -48.82% | |
2023-02-14 | Sale | Bunker Kevin D. | Chief Scientific Officer | 6,500 0.0109% | $19.98 | $129,873 | -3.41% | |
2023-02-14 | Sale | Gallagher Cam | President | 8,501 0.0143% | $19.96 | $169,706 | -3.41% | |
2023-02-14 | Sale | Epperly Melissa B, | Chief Financial Officer | 5,227 0.0088% | $19.98 | $104,411 | -3.41% |
Bunker Kevin D. | Chief Scientific Officer | 859089 1.214% | $4.16 | 1 | 41 | +70.78% |
Gallagher Cam | President | 633680 0.909% | $4.16 | 0 | 46 | |
Epperly Melissa B, | Chief Financial Officer | 451449 0.6379% | $4.16 | 3 | 18 | +21.94% |
HAUSMAN DIANA | Chief Medical Officer | 373876 0.5265% | $4.16 | 0 | 1 | |
Blackwell Kimberly | Chief Executive Officer | 254800 0.3601% | $4.16 | 1 | 4 | |
Lackner Mark | Chief Scientific Officer | 195728 0.2766% | $4.16 | 0 | 1 | |
Paul Andrea | Chief Legal Officer | 149973 0.2119% | $4.16 | 0 | 1 | |
Johnson David Michael | director | 144389 0.204% | $4.16 | 2 | 3 | +70.78% |
Brownstein Carrie | Chief Medical Officer | 105685 0.1493% | $4.16 | 0 | 1 | |
Skvarka Jan | director | 47970 0.0678% | $4.16 | 0 | 1 | |
Matrix Capital Management Company, LP | 10 percent owner | 13959973 19.727% | $4.16 | 1 | 0 | <0.0001% |
VIKING GLOBAL INVESTORS LP | 10 percent owner | 3943284 5.5723% | $4.16 | 1 | 1 | +70.78% |
SUN ANTHONY Y | President & CEO | 1175589 1.6612% | $4.16 | 1 | 30 | +70.78% |
Pinto Alexis | Chief Legal Officer | 22240 0.0314% | $4.16 | 0 | 2 | |
Voliotis Dimitris | SVP, Clinical Development | 15978 0.0226% | $4.16 | 0 | 4 |
Matrix Capital Management Company, L.P. | $220.01M | 19.66 | 13.96M | 0% | +$0 | 2.04 | |
Eventide Asset Management | $182.42M | 16.3 | 11.57M | +0.13% | +$233,972.96 | 2.87 | |
Fidelity Investments | $167.75M | 14.99 | 10.64M | +2.97% | +$4.84M | 0.01 | |
BlackRock | $73.22M | 6.54 | 4.65M | -0.84% | -$618,059.93 | <0.01 | |
The Vanguard Group | $69.32M | 6.19 | 4.4M | -17.79% | -$15M | <0.01 | |
Citadel Advisors LLC | $60.71M | 5.43 | 3.85M | +4.63% | +$2.69M | 0.04 | |
State Street | $59.66M | 5.33 | 3.79M | -14.29% | -$9.95M | <0.01 | |
T. Rowe Price | $55M | 4.91 | 3.49M | +20.17% | +$9.23M | 0.01 | |
T Rowe Price Investment Management Inc | $52.31M | 4.67 | 3.32M | +41.73% | +$15.4M | 0.03 | |
Capital International Investors | $44.44M | 3.97 | 2.82M | 0% | +$0 | 0.01 | |
Federated Hermes | $31.5M | 2.82 | 2M | -7.49% | -$2.55M | 0.07 | |
Bioimpact Capital Llc | $23.9M | 2.13 | 1.52M | New | +$23.9M | 3.87 | |
Woodline Partners LP | $22.65M | 2.02 | 1.44M | +2.38% | +$527,534.49 | 0.21 | |
Geode Capital Management | $20.53M | 1.83 | 1.3M | +3.87% | +$764,458.43 | <0.01 | |
PRIMECAP Management Co | $18.35M | 1.64 | 1.16M | +13.8% | +$2.23M | 0.01 | |
Verition Fund Management Llc | $18.21M | 1.63 | 1.16M | +235.22% | +$12.78M | 0.2 | |
Morgan Stanley | $16.35M | 1.46 | 1.04M | +70.21% | +$6.74M | <0.01 | |
Tybourne Capital Management HK Ltd | $15.15M | 1.35 | 961,486 | 0% | +$0 | 2.59 | |
Paradigm BioCapital Advisors LP | $14.89M | 1.33 | 944,917 | +136.23% | +$8.59M | 0.54 | |
Dimensional Fund Advisors | $11.4M | 1.02 | 723,656 | -0.05% | -$5,941.52 | <0.01 | |
Northern Trust | $8.25M | 0.74 | 523,702 | -1.19% | -$99,303.78 | <0.01 | |
5Am Venture Management Llc | $7.72M | 0.69 | 490,000 | 0% | +$0 | 0.52 | |
Bank of America | $7.5M | 0.67 | 475,956 | -33.77% | -$3.82M | <0.01 | |
Charles Schwab | $7.19M | 0.64 | 455,937 | +2.27% | +$159,396.64 | <0.01 | |
Boxer Capital, LLC | $7.09M | 0.63 | 450,000 | 0% | +$0 | 0.36 | |
Goldman Sachs | $5.23M | 0.47 | 332,000 | +13.36% | +$616,515.44 | <0.01 | |
Rafferty Asset Management Llc | $4.7M | 0.42 | 298,008 | -17.25% | -$978,963.90 | 0.01 | |
BNY Mellon | $4.57M | 0.41 | 289,880 | -0.09% | -$4,034.56 | <0.01 | |
UBS | $4.22M | 0.38 | 267,865 | +243,413.64% | +$4.22M | <0.01 | |
Renaissance Technologies | $4.13M | 0.37 | 261,937 | -15.31% | -$746,055.43 | 0.01 | |
Td Asset Management Inc | $4.08M | 0.36 | 258,818 | +36.1% | +$1.08M | <0.01 | |
Citigroup | $4.05M | 0.36 | 257,087 | +76.19% | +$1.75M | <0.01 | |
Millennium Management LLC | $3.88M | 0.35 | 246,322 | +702.48% | +$3.4M | <0.01 | |
Two Sigma | $3.86M | 0.35 | 244,995 | New | +$3.86M | 0.01 | |
Opaleye Management Inc | $3.15M | 0.28 | 200,000 | New | +$3.15M | 0.5 | |
Mayo Clinic | $2.95M | 0.26 | 187,143 | 0% | +$0 | 49.76 | |
Voya Investment Management LLC | $2.28M | 0.2 | 144,623 | -2.84% | -$66,696.34 | <0.01 | |
The Manufacturers Life Insurance Company | $2.08M | 0.19 | 131,815 | +12.77% | +$235,154.92 | <0.01 | |
PDT Partners | $2.07M | 0.19 | 131,263 | New | +$2.07M | 0.16 | |
Nuveen | $2.05M | 0.18 | 130,308 | 0% | +$0 | <0.01 | |
Jane Street Capital | $1.96M | 0.18 | 124,287 | +170.14% | +$1.23M | <0.01 | |
Jump Financial Llc | $1.87M | 0.17 | 118,648 | New | +$1.87M | 0.02 | |
Hrt Financial Llc | $1.79M | 0.16 | 113,750 | New | +$1.79M | 0.01 | |
Two Sigma Advisers LP | $1.59M | 0.14 | 101,000 | New | +$1.59M | <0.01 | |
Swiss National Bank | $1.54M | 0.14 | 97,400 | 0% | +$0 | <0.01 | |
Marshall Wace | $1.4M | 0.13 | 89,012 | 0% | +$0 | <0.01 | |
RhumbLine Advisers | $1.3M | 0.12 | 82,762 | +2.43% | +$30,920.81 | <0.01 | |
Values First Advisors, Inc. | $1.12M | 0.1 | 71,066 | +47.84% | +$362,447.46 | 0.25 | |
Ubs Asset Management Americas Inc | $1.06M | 0.1 | 67,472 | +6.8% | +$67,705.04 | <0.0001 | |
Barclays | $1.04M | 0.09 | 66,317 | -69.79% | -$2.41M | <0.0001 |